Liquidia (NASDAQ:LQDA) Coverage Initiated at Wells Fargo & Company

Wells Fargo & Company began coverage on shares of Liquidia (NASDAQ:LQDA) in a report released on Friday, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $20.00 price target on the stock.

Several other research firms also recently commented on LQDA. Lifesci Capital began coverage on shares of Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price objective for the company. Scotiabank assumed coverage on Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $29.00 target price on shares of Liquidia in a research report on Thursday, November 14th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $19.00 target price on shares of Liquidia in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Liquidia has a consensus rating of “Moderate Buy” and a consensus price target of $23.60.

Liquidia Stock Performance

NASDAQ LQDA opened at $11.10 on Friday. Liquidia has a fifty-two week low of $8.26 and a fifty-two week high of $16.99. The company has a market capitalization of $939.47 million, a PE ratio of -6.81 and a beta of 0.22. The business’s fifty day moving average is $10.91 and its 200 day moving average is $11.18.

Insider Transactions at Liquidia

In related news, insider Rajeev Saggar sold 2,260 shares of Liquidia stock in a transaction on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $25,108.60. Following the sale, the insider now directly owns 207,383 shares in the company, valued at $2,304,025.13. This trade represents a 1.08 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael Kaseta sold 3,892 shares of Liquidia stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $43,240.12. Following the transaction, the chief financial officer now directly owns 311,076 shares in the company, valued at approximately $3,456,054.36. This trade represents a 1.24 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,007 shares of company stock valued at $245,780. 30.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Liquidia

A number of hedge funds have recently added to or reduced their stakes in LQDA. Whitefort Capital Management LP grew its holdings in Liquidia by 119.8% in the third quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock valued at $17,020,000 after purchasing an additional 927,546 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Liquidia by 144.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock valued at $3,903,000 after buying an additional 230,820 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Liquidia by 18.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 207,961 shares of the company’s stock worth $2,496,000 after purchasing an additional 32,076 shares during the last quarter. HighVista Strategies LLC lifted its position in Liquidia by 48.6% in the third quarter. HighVista Strategies LLC now owns 180,947 shares of the company’s stock worth $1,809,000 after purchasing an additional 59,193 shares during the period. Finally, Wellington Management Group LLP boosted its stake in Liquidia by 12.5% during the 3rd quarter. Wellington Management Group LLP now owns 179,923 shares of the company’s stock valued at $1,799,000 after purchasing an additional 19,932 shares in the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).